Scientific Program


Thursday, April 28, 2016
COMy Special Pre-Congress
Session
15:15-17:15
THE PATIENTS' PERSPECTIVE
 
  
Session speakers:
 
 
 
 
   
B. Delcour, France
D. Nabias, France
E. Poisson, France
T. Barbieux, Belgium
E. Low, UK
H. Scheurer, The Netherlands
  
Opening Session
17:45-20:00

 
Chairs:
 
M. Mohty, France, A. Nagler, Israel and T. Facon, France
 
17:45-18:00
Welcome Address: M. Mohty, France, A. Nagler, Israel and T. Facon, France
18:00-18:30 MGUS: A journey in time: R. Kyle, USA
18:30-19:00
Access to novel drugs in myeloma: J.L. Harousseau, France
19:00-19:45
 
  
Congress Award Ceremony
Multiple myeloma achievement award lectures:
P. Richardson, USA and A. Palumbo, Italy
&
Basic and translational research multiple myeloma award lecture:
H. Avet-Loiseau, France
19:45-20:00
 
Discussion
 

20:00-21:00 Welcome Reception
 
Friday, April 29, 2016
Session 1
08:30-10:00
BIOLOGY OF THE DISEASE
  
Chair:
 
H. Avet-Loiseau, France
 
08:30-08:50
Prognostic factors: H. Avet-Loiseau, France
08:50-09:10
Role of the microenvironment: T. Mutis, The Netherlands
09:10-09:30
Myeloma nephropathy: N. Leung, USA
09:30-09:50 Monoclonal gammopathy of clinical significance: J.P. Fermand, France
09:50-10:00
  
Discussion
 
10:00-10:30 Coffee Break
Session 2
10:30-12:00
IMAGING AND DISEASE ASSESSMENT
  
Chair:
  
E. Terpos, Greece
  
10:30-10:55 PET scan and MRI: E. Terpos, Greece
10:55-11:20 Minimal residual disease: B. Paiva, Spain
11:20-11:45 Disease response assessment: C. Fernandez de Larrea, Spain
11:45-12:00
 
Discussion
 
12:00-12:15  Lunch Box Pick-up
12:15-13:30
  
Lunch Symposium
  
13:30-13:45 Break
Session 3
13:45-14:30
SPECIAL LECTURES
  
Chair:
  
X. Leleu, France
  
13:45-14:05 Advances in amyloidosis: A. Jaccard, France
14:05-14:25
Waldenstrom update: X. Leleu, France
14:25-14:30
 
Discussion
  
Session 4
14:30-16:00
FRONTLINE THERAPY
  
Chair:
  
P. Moreau, France and A. Palumbo, Italy 
  
14:30-14:55 Treatment of the elderly: T. Facon, France
14:55-15:20 Transplant-eligible patients: P. Moreau, France
15:20-15:40 Consolidation and maintenance: P. Richardson, USA
15:40-16:00
 
Discussion
  
16:00-16:20 Coffee Break
Session 5
16:20-16:45
SPECIAL LECTURE
 
Chair:
 
P. Richardson, USA

16:20-16:45 Total therapy: An update: B. Barlogie, USA
 

Session 6
16:45-18:30
INNOVATIVE APPROACHES AND CASE DISCUSSIONS
 
Chair:
 
M. Mohty, France
 
16:45-17:00
Role of check-point inhibitors: P. Rodriguez, Spain
17:00-17:15
Role of HDAC inhibitors: M. Mohty, France
17:15-18:30 Clinical cases
Moderator: L. Garderet, France
   - Case no.1: B. Hebraud, France
   - Case no. 2: E. Boyle, France
   - Case no. 3: L. Garderet, France
  

Saturday, April 30, 2016
Special session
07:30-08:30
INTERNATIONAL MULTIPLE MYELOMA COLLABORATION (IM2C®)
 
Chairs:
  
S. Lonial, USA and M. Mohty, USA
  
07:30-07:45 The Japanese perspective: The hot topics: K. Shimizu, Japan
07:45-08:00 The Chinese perspective: Ongoing research: W.M. Chen, China
08:00-08:15 The Indian perspective: Current situation: L. Kumar, India
08:15-08:30
  
Roundtable debate: East and West collaborations: Speaker and Chairs
 
Session 7
08:30-09:30
SMOLDERING MYELOMA
 
Chair:
 
M.V. Mateos, Spain
 
08:30-08:55 Diagnostic criteria: A. Palumbo, Italy
08:55-09:20 Therapy: M.V. Mateos, Spain
09:20-09:30
 
Discussion
  
Session 8
09:30-11:00
TREATMENT OF RELAPSE
 
Chair:
 
S. Lonial, USA
  
09:30-09:55 IMiDs: X. Leleu, France
09:55-10:20 Proteasome inhibitors: M. Delforge, Belgium
10:20-10:45 Monoclonal antibodies: S. Lonial, USA
10:45-11:00
Discussion
 
11:00-11:30 Coffee Break
Session 9
11:30-13:00
SPECIFIC APPROACHES
 
Chair:
 
M. Roussel, France
 
11:30-11:55 Frailty assessment and adjustment of therapy: S. Zweegman, The Netherlands
11:55-12:20 Role of 2nd autologous transplantation: M. Cavo, Italy
12:20-12:45 Optimal sequence of therapy at relapse, especially the use of 2nd generation proteasome inhibitors: M. Mohty, France
12:45-13:00
 
Discussion
 
13:00-13:15 Lunch Box Pick-up
13:15-14:30
  
LUNCH SYMPOSIUM
  
14:30-14:45
Break
Session 10
14:45-15:45
IMMUNOTHERAPY
  
Chairs:

H. Einsele, Germany
 
14:45-15:05 Treatment of high risk myeloma: P. Sonneveld, The Netherlands
15:05-15:25 Allogeneic stem cell transplantation: A. Nagler, Israel
15:25-15:45 Immunotherapy: H. Einsele, Germany

   
Closing Session
15:45-16:30
 
Chairs:
 
M. Mohty, France, A. Nagler, Israel and T. Facon, France
 
15:45-16:05 The future: M. Attal, France
16:05-16:15 Discussion
16:15-16:30
 
Closing address: M. Mohty, France, A. Nagler, Israel and T. Facon, France